Danish allergy immunotherapy specialist ALK Abello has entered into a strategic license agreement with US-based ARS ...

Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi ...

According to the Swedish pharma trade group Lif, it is positive that, in the updated life science strategy, the government expresses an ambition for Sweden to become more attractive for research ...

Li Li, Commissioner of China's National Medical Products Administration (NMPA), and Mette Aaboe Hansen, interim director ...

In its third quarter results of 2024, pharmaceutical giant GSK confirmed it would pay a quarterly dividend of 15 pence. However, Morningstar analyst Christopher Johnson says he believes that GSK’s ...

The Parkinson’s disease (PD) therapeutic landscape is heavily genericized, leaving substantial unmet needs in neuroprotective ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

New research has been published in the Journal of Allergy and Clinical Immunology (JACI) that shows treatment with ...

South Korea’s Alteogen (Kosdaq: 196170) has signed an exclusive licensing agreement with Japanese pharmaceutical company ...

"A dynamic and versatile pharmaceutical company with regional horizons in Latin America." "Axon Pharma is an independent multinational pharmaceutical company built on high-standards science and ...

Dizal has submitted an application to the US FDA for sunvozertinib, an oral EGFR inhibitor for advanced NSCLC with EGFR exon 20 insertion mutations, aimed at patients after platinum-based chemotherapy ...

Viracta Therapeutics has announced a restructuring to focus on its lead oncology candidate, nana-val, targeting EBV-positive ...